npub13us8dx3eaa9x4am506elrml8tjlw3v54cfwmr8sx7p3al97gxqvs5uqafs (npub13us…qafs) npub1vu7uztz0rtxpejd095nl7k78kangchcu58s7cpnt05un5l2n9rsshgnmuv (npub1vu7…nmuv) npub1psdfxfpxz2cwmmnsk60y3nqpn2tqh9n24h4hstvfkwvr6eaek9js499sr7 (npub1psd…9sr7)
I think the exorbitant salary packages to the corporate heads is likely a bigger negative revenue. Companies also get tax write offs, public money to research and public research for free for commercialization. If you count executive compensation & perks, you'll find the bigger drains there. Most pharmaceutical companies also give big dividends, which means they need to generate constant or increasing/predictable profits (overcharging) which also have to come from pts